» Articles » PMID: 33443063

A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After Lu-DOTATATE

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2021 Jan 14
PMID 33443063
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple-time-point SPECT/CT imaging for dosimetry is burdensome for patients and lacks statistical efficiency. A novel method for joint kidney time-activity estimation based on a statistical mixed model, a prior cohort of patients with complete time-activity data, and only 1 or 2 imaging points for new patients was compared with previously proposed single-time-point methods in virtual and clinical patient data. Data were available for 10 patients with neuroendocrine tumors treated with Lu-DOTATATE and imaged up to 4 times between days 0 and 7 using SPECT/CT. Mixed models using 1 or 2 time points were evaluated retrospectively in the clinical cohort, using the multiple-time-point fit as the reference. Time-activity data for 250 virtual patients were generated using parameter values from the clinical cohort. Mixed models were fit using 1 (∼96 h) and 2 (4 h, ∼96 h) time points for each virtual patient combined with complete data for the other patients in each dataset. Time-integrated activities (TIAs) calculated from mixed model fits and other reduced-time-point methods were compared with known values. : All mixed models and single-time-point methods performed well overall, achieving mean bias < 7% in the virtual cohort. Mixed models exhibited lower bias, greater precision, and substantially fewer outliers than did single-time-point methods. For clinical patients, 1- and 2-time-point mixed models resulted in more accurate TIA estimates for 94% (17/18) and 72% (13/18) of kidneys, respectively. In virtual patients, mixed models resulted in more than a 2-fold reduction in the proportion of kidneys with |bias| > 10% (6% vs. 15%). Mixed models based on a historical cohort of patients with complete time-activity data and new patients with only 1 or 2 SPECT/CT scans demonstrate less bias on average and significantly fewer outliers when estimating kidney TIA, compared with popular reduced-time-point methods. Use of mixed models allows for reduction of the imaging burden while maintaining accuracy, which is crucial for clinical implementation of dosimetry-based treatment.

Citing Articles

Prediction of 1 cm dose-equivalent rate on the day after administration of Lu-DOTATATE from In-somatostatine receptor scintigraphy prior to treatment.

Takai G, Hanaoka K, Nagano K, Okada T, Honda M, Komoto I Ann Nucl Med. 2024; 38(11):927-932.

PMID: 39060833 DOI: 10.1007/s12149-024-01962-0.


Estimation of kidney doses from [Lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT/CT.

Spink S, Gillett D, Heard S, Harper I, Casey R, Aloj L EJNMMI Phys. 2024; 11(1):68.

PMID: 39052172 PMC: 11272758. DOI: 10.1186/s40658-024-00665-9.


A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?.

Vergnaud L, Dewaraja Y, Giraudet A, Badel J, Sarrut D EJNMMI Phys. 2024; 11(1):65.

PMID: 39023648 PMC: 11554969. DOI: 10.1186/s40658-024-00658-8.


Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [Lu]Lu-PSMA-I&T Therapy.

Resch S, Ziegler S, Sheikh G, Unterrainer L, Zacherl M, Bartenstein P J Nucl Med. 2024; 65(8):1272-1278.

PMID: 38936975 PMC: 11294067. DOI: 10.2967/jnumed.123.266871.


Uncertainty Analysis of Time-Integrated Activity Coefficient in Single-Time-Point Dosimetry Using Bayesian Fitting Method.

Jundi A, Naqiyyun M, Patrianesha B, Muminah I, Riana A, Hardiansyah D Nucl Med Mol Imaging. 2024; 58(3):120-128.

PMID: 38633290 PMC: 11018592. DOI: 10.1007/s13139-024-00851-8.


References
1.
Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P . Individualised Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017; 44(9):1480-1489. PMC: 5506097. DOI: 10.1007/s00259-017-3678-4. View

2.
Sandstrom M, Garske-Roman U, Johansson S, Granberg D, Sundin A, Freedman N . Kidney dosimetry during Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta Oncol. 2017; 57(4):516-521. DOI: 10.1080/0284186X.2017.1378431. View

3.
Hanscheid H, Lapa C, Buck A, Lassmann M, Werner R . Dose Mapping After Endoradiotherapy with Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. J Nucl Med. 2017; 59(1):75-81. DOI: 10.2967/jnumed.117.193706. View

4.
Madsen M, Menda Y, ODorisio T, ODorisio M . Technical Note: Single time point dose estimate for exponential clearance. Med Phys. 2018; 45(5):2318-2324. PMC: 5948162. DOI: 10.1002/mp.12886. View

5.
Willowson K, Eslick E, Ryu H, Poon A, Bernard E, Bailey D . Feasibility and accuracy of single time point imaging for renal dosimetry following Lu-DOTATATE ('Lutate') therapy. EJNMMI Phys. 2018; 5(1):33. PMC: 6300448. DOI: 10.1186/s40658-018-0232-9. View